ReviewCurrent topics in medicinal chemistry2026
Network Pharmacology as a Tool to Explore the Therapeutic Mechanism of
Review in Current topics in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated Network Pharmacology and Molecular Dynamics Reveal Luteolin fromInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionConsidering the shared physiological mechanisms between type 2 diabetes (T2D) and colorectal cancer (CRC), it is plausible that certain compounds may exert therapeutic effects on both diseases. Opuntia ficus-indica (nopal) has been traditionally used to manage these conditions. This study aims to elucidate the molecular mechanisms through which nopal exerts its effects on T2D and CRC.
methodsBioactive compounds of nopal, their molecular targets, and genes associated with T2D and CRC were identified from public databases. Gene Ontology (GO) analysis, metabolic pathway analysis, protein-protein interaction (PPI) network construction, and molecular docking were conducted to investigate the shared molecular targets.
resultsNopal contains bioactive compounds that interact with molecular targets common to both T2D and CRC. These shared targets are implicated in lipid metabolism, apoptosis, kinase activity, interleukin-related pathways (IL-2 and IL-3), inflammation, gastrin signaling, and other critical processes. Key molecular targets identified include HSP90AA1 and MAPK8, while the principal bioactive compounds of nopal are eriodictyol and aromadendrin. DISCUSSION: The identification of eriodictyol and aromadendrin as modulators of HSP90AA1 and MAPK8 elucidates a pleiotropic mechanism underlying the link between type 2 diabetes and colorectal cancer. By modulating apoptotic and inflammatory pathways, these bioactive compounds offer a promising foundation for developing dual-action therapies targeting both metabolic and oncogenic pathways in patients with comorbid conditions.
conclusionThe bioactive compounds of nopal engage multiple biological pathways relevant to T2D and CRC, suggesting that this plant may serve as a promising pharmacological candidate for the management of these diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.